This model confirms the clinical observation that the IDH mutation increases median survival in the absence of treatment, enhances DNA damage response (DDR) via epigenetic upregulation of the ataxia‐telangiectasia–mutated (ATM) signalling pathway, and elicits tumour radio‐resistance [191]. The gene discussed is IDH2; the disease is neoplasm.